Biofrontera Announces FDA Approval of Ameluz Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
RegulatoryapprovedAmeluzPositive
AI Analysis
Summary
Biofrontera announced FDA approval of Ameluz Red Light PDT for treating superficial basal cell carcinoma, a major regulatory milestone for the company's photodynamic therapy dermatology portfolio.
Outcome Details
FDA Approval of Ameluz Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Importance:8/10
Sentiment:
0.90
FDA approvalphotodynamic therapydermatologybasal cell carcinoma
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 14, 2026 8:09 PM